The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Copper‐Enriched Prussian Blue Nanomedicine for In Situ Disulfiram Toxification and Photothermal Antitumor Amplification
Abstract
In situ toxification of less toxic substance for the generation of effective anticarcinogens at the specific tumor tissue has been a novel paradigm for combating cancer. Significant efforts have been recently dedicated to turning clinical‐approved drugs into anticancer agents in specific tumor microenvironment by chemical reactions. Herein, a hollow mesoporous Prussian blue (HMPB)‐based therapeutic nanoplatform, denoted as DSF@PVP/Cu‐HMPB, is constructed by encapsulating alcohol‐abuse drug disulfiram (DSF) into the copper‐enriched and polyvinylpyrrolidone (PVP)‐decorated HMPB nanoparticles to achieve in situ chemical reaction‐activated and hyperthermia‐amplified chemotherapy of DSF. Upon tumor accumulation of DSF@PVP/Cu‐HMPB, the endogenous mild acidity in tumor condition triggers the biodegradation of the HMPB nanoparticle and the concurrent co‐releases of DSF and Cu 2+, thus forming cytotoxic bis(N,N‐diethyl dithiocarbamato)copper(II) complexes (CuL 2) via DSF‐Cu 2+ chelating reaction. Moreover, by the intrinsic photothermal‐conversion effect of PVP/Cu‐HMPBs, the anticancer effect of DSF is augmented by the hyperthermia generated upon near‐infrared irradiation, thus inducing remarkable cell apoptosis in vitro and tumor elimination in vivo on both subcutaneous and orthotopic tumor‐bearing models. This strategy of in situ drug transition by chemical chelation reaction and photothermal‐augmentation provides a promising paradigm for designing novel cancer‐therapeutic nanoplatforms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A view on drug resistance in cancer
Vasan, N., Baselga, J., & Hyman, D. M. (2019) · Nature · doi:10.1038/s41586-019-1730-1 · Cited by 2,770
Revisiting the role of ABC transporters in multidrug-resistant cancer
Robey, R. W., Pluchino, K. M., Hall, M. D., Fojo, A. T., Bates, S. E., & Gottesman, M. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0005-8 · Cited by 1,866
Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion
Leone, R. D., Zhao, L., Englert, J. M., Sun, I.-M., Oh, M.-H., Sun, I.-H., Arwood, M. L., Bettencourt, I. A., Patel, C. H., Wen, J., et al. (2019) · Science · doi:10.1126/science.aav2588 · Cited by 1,169
Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4
Skrott, Z., Mistrik, M., Andersen, K. K., Friis, S., Majera, D., Gursky, J., Ozdian, T., Bartkova, J., Turi, Z., Moudry, P., et al. (2017) · Nature · doi:10.1038/nature25016 · Cited by 807
Cited by
The recent progress on metal–organic frameworks for phototherapy
Zheng, Q., Liu, X., Zheng, Y., Yeung, K. W. K., Cui, Z., Liang, Y., Li, Z., Zhu, S., Wang, X., & Wu, S. (2021) · Chemical Society Reviews · doi:10.1039/d1cs00056j · Cited by 491
Recent Advances in Hyperthermia Therapy‐Based Synergistic Immunotherapy
Chang, M., Hou, Z., Wang, M., Li, C., & Lin, J. (2021) · Advanced Materials · doi:10.1002/adma.202004788 · Cited by 450
Tannic acid-based metal phenolic networks for bio-applications: a review
Guo, Z., Xie, W., Lu, J., Guo, X., Xu, J., Xu, W., Chi, Y., Takuya, N., Wu, H., & Zhao, L. (2021) · Journal of Materials Chemistry B · doi:10.1039/d1tb00383f · Cited by 375
A Multichannel Ca2+ Nanomodulator for Multilevel Mitochondrial Destruction‐Mediated Cancer Therapy
Zheng, P., Ding, B., Shi, R., Jiang, Z., Xu, W., Li, G., Ding, J., & Chen, X. (2021) · Advanced Materials · doi:10.1002/adma.202007426 · Cited by 300
Jiang, Y., Huo, Z., Qi, X., Zuo, T., & Wu, Z. (2022) · Nanomedicine · doi:10.2217/nnm-2021-0374 · Cited by 276
Metadata
- Authors
- Wu, W., Yu, L., Pu, Y., Yao, H., Chen, Y., & Shi, J.
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2020-03-12
- Volume
- 32
- Issue
- 17
- Pages
- e2000542-e2000542
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- OpenAlex
- W3011328293
- Cited by
- 211
- References
- 4
- FWCI
- 8.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.